<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742716</url>
  </required_header>
  <id_info>
    <org_study_id>CTA018-CL-2002</org_study_id>
    <nct_id>NCT00742716</nct_id>
  </id_info>
  <brief_title>Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease</brief_title>
  <official_title>An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO IP Holdings II, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK)
      in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT),
      undergoing regular hemodialysis. This study will also investigate the safety and effects of
      different strengths of CTA018, on parathyroid hormone (PTH) levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the single and repeat dose pharmacokinetics (PK) of CTA018 Injection</measure>
    <time_frame>Day 1 and 12 of each dose level</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the safety of CTA018 Injection</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacodynamic (PD) intact parathyroid hormone (iPTH) response following CTA08 Injection</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the efficacy of CTA018 Injection to reduce serum iPTH</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>CTA018 Injection low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose IV 3 times a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTA018 Injection low to mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low to mid dose IV 3 times a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTA018 Injection mid to high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mid to high dose IV 3 times a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTA018 Injection high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose IV 3 times a week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTA018 Injection</intervention_name>
    <description>Comparison of different dosages of drug</description>
    <arm_group_label>CTA018 Injection low dose</arm_group_label>
    <arm_group_label>CTA018 Injection low to mid dose</arm_group_label>
    <arm_group_label>CTA018 Injection mid to high dose</arm_group_label>
    <arm_group_label>CTA018 Injection high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 18 and 35

          -  On maintenance hemodialysis three times per week

          -  Serum iPTH value greater than or equal to 300 pg/mL and lower than or equal to 1000
             pg/mL

          -  Adjusted or total serum calcium value greater than or equal to 8.4 mg/dL and lower
             than 10.0 mg/dL

          -  Serum phosphorus value greater than or equal to 2.5 mg/dL and lower than or equal to
             5.5 mg/dL

          -  Serum 25-hydroxyvitamin D level greater than or equal to 15 ng/mL

          -  Willing and able to discontinue vitamin D and/or bone metabolism therapy for at least
             2 weeks prior to administration of Study Drug, and the length of study

        Exclusion Criteria:

          -  On bisphosphonates for at least three months prior to first dose of Study Drug

          -  Currently taking cytochrome P450 3A inhibitors and/or inducers

          -  Abnormal liver functions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>OPKO Renal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pines Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boise Kidney and Hypertension Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New England Renal &amp; Transplant Associates (WNERTA)</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107-1121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S. Renal Care</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Heatlth Authority: Centre for Clinical Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5N 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Coeur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Verdun</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4G 2A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <disposition_first_submitted>October 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 6, 2014</disposition_first_posted>
  <last_update_submitted>October 30, 2014</last_update_submitted>
  <last_update_submitted_qc>October 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parathyroid Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Hyperparathyroidism, Secondary</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Kidney Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

